Skandinaviska Enskilda Banken AB publ Has $6.15 Million Stake in Natera, Inc. (NASDAQ:NTRA)

Skandinaviska Enskilda Banken AB publ lowered its stake in Natera, Inc. (NASDAQ:NTRA - Free Report) by 73.0% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 38,799 shares of the medical research company's stock after selling 104,959 shares during the period. Skandinaviska Enskilda Banken AB publ's holdings in Natera were worth $6,150,000 as of its most recent filing with the SEC.

Other large investors have also recently bought and sold shares of the company. Blue Trust Inc. lifted its holdings in shares of Natera by 104.3% during the fourth quarter. Blue Trust Inc. now owns 190 shares of the medical research company's stock worth $30,000 after buying an additional 97 shares in the last quarter. Versant Capital Management Inc raised its stake in Natera by 345.8% in the 4th quarter. Versant Capital Management Inc now owns 214 shares of the medical research company's stock worth $34,000 after purchasing an additional 166 shares in the last quarter. Covestor Ltd grew its position in shares of Natera by 34.3% during the 3rd quarter. Covestor Ltd now owns 372 shares of the medical research company's stock worth $47,000 after purchasing an additional 95 shares in the last quarter. EverSource Wealth Advisors LLC increased its holdings in shares of Natera by 372.9% during the fourth quarter. EverSource Wealth Advisors LLC now owns 331 shares of the medical research company's stock worth $52,000 after purchasing an additional 261 shares during the period. Finally, Principal Securities Inc. increased its holdings in shares of Natera by 20.7% during the fourth quarter. Principal Securities Inc. now owns 344 shares of the medical research company's stock worth $54,000 after purchasing an additional 59 shares during the period. 99.90% of the stock is owned by institutional investors.

Remove Ads

Insider Buying and Selling

In other news, Director Gail Boxer Marcus sold 4,000 shares of the firm's stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $147.69, for a total transaction of $590,760.00. Following the completion of the sale, the director now owns 9,704 shares of the company's stock, valued at $1,433,183.76. This trade represents a 29.19 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Also, insider Solomon Moshkevich sold 6,000 shares of Natera stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $143.29, for a total transaction of $859,740.00. Following the completion of the sale, the insider now owns 143,768 shares of the company's stock, valued at $20,600,516.72. This represents a 4.01 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 298,946 shares of company stock valued at $47,803,462 over the last 90 days. Company insiders own 7.60% of the company's stock.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on NTRA. JPMorgan Chase & Co. increased their price objective on shares of Natera from $160.00 to $200.00 and gave the stock an "overweight" rating in a research note on Friday, December 13th. BTIG Research restated a "buy" rating on shares of Natera in a research report on Friday, February 28th. The Goldman Sachs Group raised their price objective on Natera from $160.00 to $190.00 and gave the company a "buy" rating in a research note on Tuesday, January 28th. Morgan Stanley boosted their target price on Natera from $176.00 to $185.00 and gave the stock an "overweight" rating in a research note on Wednesday, March 5th. Finally, Royal Bank of Canada assumed coverage on shares of Natera in a research note on Thursday, March 13th. They issued an "outperform" rating and a $251.00 price target on the stock. One investment analyst has rated the stock with a hold rating and sixteen have given a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $178.12.

Natera Trading Up 3.1 %

Shares of NASDAQ:NTRA traded up $4.59 during trading on Wednesday, reaching $150.87. The stock had a trading volume of 2,162,889 shares, compared to its average volume of 1,346,669. Natera, Inc. has a 52 week low of $83.13 and a 52 week high of $183.00. The company has a debt-to-equity ratio of 0.33, a quick ratio of 4.23 and a current ratio of 4.39. The firm's fifty day moving average is $162.76 and its 200 day moving average is $149.26. The stock has a market cap of $20.40 billion, a price-to-earnings ratio of -85.72 and a beta of 1.80.

Natera (NASDAQ:NTRA - Get Free Report) last issued its quarterly earnings results on Thursday, February 27th. The medical research company reported ($0.41) EPS for the quarter, beating analysts' consensus estimates of ($0.42) by $0.01. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. The business had revenue of $476.10 million for the quarter, compared to analysts' expectations of $447.91 million. As a group, equities analysts forecast that Natera, Inc. will post -1.49 EPS for the current fiscal year.

Natera Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.